Latest Headlines

Latest Headlines

Diagnostics companies jump into rapidly growing market for point-of-care superbug tests

As drug-resistant superbug infections continue to rise, diagnostics companies are rolling out rapid, point-of-care devices that can quickly identify infectious bacteria and potentially cut down on the need for unnecessary antibiotics, cashing in on a growing market for the tools.

Alere revs up engine with new deals and win for quick strep test

Alere recently sold its BBI Diagnostics unit, snatched up a new diagnostics company and grabbed an FDA CLIA waiver for its quick strep test as part of its turnaround plan.

Alere keeps diagnostics ball rolling with new deals and quick strep test win

Alere recently sold off its BBI Diagnostics unit, scooped up a new diagnostics company and nabbed an FDA CLIA waiver for its quick strep test, helping the company distance itself from its troubled past.

Alere earns FDA clearance for rapid diagnostic of Strep A

Alere announced FDA clearance of its Alere i Strep A test to detect Strep A bacteria in 8 minutes or less using throat swab specimens.

Alere snags first FDA CLIA waiver for molecular influenza test

Alere won an FDA CLIA waiver for its molecular influenza test, giving the company a boost amid restructuring efforts and putting its diagnostic in the hands of more healthcare professionals as flu season reaches epidemic status.

UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring

Alere continued down the path of deleveraging and refocusing on its core competency in diagnostics with the sale of its Alere Health unit to Optum, a part of the insurance company UnitedHealth Group for $600 million.

Alere close to sale of health management unit

Alere management is in advanced talks to sell its health management business, according to Reuters. In August, the diagnostics player had said it would do so before year-end as part of an ongoing strategic review aimed at returning the company to revenue and earnings growth.

Former Alere execs assemble $3.8B take-private offer

Former Alere executives are putting together a $46-per-share takeover offer for the diagnostics company, according to a Sept. 15 SEC filing. Investors didn't embrace the offer entirely, but they did send shares up about 13% to $41.33 in midafternoon trading.

Alere to complete strategic review by year-end

In the midst of a management transition, diagnostic company Alere missed its quarterly numbers. The company acknowledged its recent problems and missteps as well as started to outline a new strategic vision for Alere that will become clearer to investors around the end of this year, when a comprehensive review will be finished.

Alere rethinks BBI IPO

So much for those IPO plans. Alere last week decided against taking its BBI Diagnostics businesses public on the London Stock Exchange, citing equity market conditions in the U.K.